Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FLOVENT HFA Clear all
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

NCT00318708
View directory record Official record
Conditions
Asthma
Interventions
clarithromycin, fluticasone propionate, placebo clarithromycin
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional

Effect of Age and Device on Delivery of Fluticasone

NCT00308932
View directory record Official record
Conditions
Asthma
Interventions
HFA FP MDI
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

NCT00747318
View directory record Official record
Conditions
Asthma
Interventions
SKP FlutiForm HFA pMDI
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 4, 2026, 7:34 AM EDT
Terminated Phase 4 Interventional

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

NCT00071552
View directory record Official record
Conditions
Asthma
Interventions
Qvar, Flovent Diskus
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 4, 2026, 7:34 AM EDT
Active, not recruiting No phase listed Observational

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

NCT05309590
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dose
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

MethaCholine Bronchoprovocation Study (MeCIS)

NCT00705341
View directory record Official record
Conditions
Asthma
Interventions
fluticasone
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
12 Years to 69 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
13
States / cities
San Diego, California • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Not applicable Interventional Results available

DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?

NCT01184118
View directory record Official record
Conditions
Lung Disease
Interventions
FP 220 mcg 2 puffs BID
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 4, 2026, 7:34 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

NCT00452348
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Results available

Fall Epidemic Viral Pediatric Study

NCT01192178
View directory record Official record
Conditions
Asthma
Interventions
FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
38
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 1 Interventional

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

NCT02437604
View directory record Official record
Conditions
Asthma
Interventions
Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 4, 2026, 7:34 AM EDT
Recruiting Phase 2 Interventional

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

NCT06705387
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Fluticasone
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

NCT02593123
View directory record Official record
Conditions
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Interventions
mycophenolate mofetil, Sargramostim, Filgrastim
Drug · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR HFA, ADVAIR DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Huntington Beach, California • Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Results available

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

NCT01462344
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
267
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 4, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

NCT01396278
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone propionate, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
37
States / cities
Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 4, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Flovent in Patients With Eosinophilic Esophagitis

NCT00426283
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Flovent, Placebo
Drug · Other
Lead sponsor
Marc Rothenberg, MD
Other
Eligibility
3 Years to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Results available

Individualizing Treatment for Asthma in Primary Care

NCT06272370
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Interventions
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
Other · Drug
Lead sponsor
DARTNet Institute
Government
Eligibility
12 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 4, 2026, 7:34 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

NCT01702701
View directory record Official record
Conditions
Eosinophilic Esophagitis, Dysphagia
Interventions
Montelukast, Fluticasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Not applicable Interventional Results available

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019
View directory record Official record
Conditions
Allergic Asthma
Interventions
salmeterol, Fluticasone, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 4, 2026, 7:34 AM EDT